https://medicalnewsmiami.com/adagene-presents-interim-monotherapy-data-at-esmo-2022-showing-compelling-safety-anti-tumor-activity-and-pharmacokinetics-of-masked-anti-ctla-4-safebody-adg126-in-patients-with-advanced-tumors/